Category: Clinical Trials
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
2025 Worldwide ALK TKI Revenues Exceed Three Billion Dollars
Article by Jeff Sturm, Patient and Board Member, ALK Positive Inc.
-
NXP900 + Lorlatinib: Blocking a Potential ALK Bypass Pathway
Clinical Trial ID NCT07784959 Phase Ib Study of NXP900 With Lorlatinib in ALK+ Lung Cancer Sponsored by Nuvectis Pharma, Inc.
-
New Phase 1 Trial Will Explore AQUA07 in ALK-positive NSCLC
Clinical Trial ID NCT07617337
-
Clinical Trials Update: ALK Research Makes a Big Splash @ The ASCO Conference
New Hope from ASCO 2026 Each year, the American Society of Clinical Oncology (ASCO) hosts cancer researchers from around the world to share their latest discoveries. At this year’s meeting in Chicago, researchers presented many new findings on ALK-positive lung cancer. The overall message was encouraging: targeted therapies continue to improve outcomes, treatment options are expanding, and researchers are finding…
-
Ivonescimab: A phase 2 Clinical Trial NCT07405190 by Akeso, Inc.
Clinical Trial ID NCT07405190
-
Patient Perspective: Hope for ALK+ NSCLC Patients
Jeff Sturm reflects on the emotional reality of living with ALK-positive cancer and the role gratitude, kindness, and community can play in helping patients and families hold onto hope.
-
Clinical Trials Update: TRI-116: Molecular Glue Degraders for Dummies
The ALK-positive community is buzzing about a cutting-edge clinical trial currently recruiting for those with ALK-positive lung cancer. The experimental medication TRI-116 is an ALK molecular glue degrader. A Google search of “molecular glue degrader for cancer” will lead you to terms like proteasome, ubiquitin, and E3 ligase. If your eyes glaze over when you…
-
Six Facts About Clinical Research Participation for ALK-Positive Lung Cancer Patients
by Dr. Ken Culver, Executive Director and Medical Director, ALK Positive, Inc.
-
-
Patient Perspective: Alternative Nuvalent drug for patients disqualified from NVL-655 due to liver toxicity
Jeff Sturm shares his experience accessing the investigational drug zidesamtinib through a single-patient IND after discontinuing the NVL-655 trial due to liver toxicity. His story highlights how physicians, researchers, and companies sometimes work together to explore additional options for patients.
-
True or False: Test Your Knowledge of Clinical Trials
Clinical trials are often misunderstood. This short quiz explores common myths and facts about trials, helping patients better understand participation, safety, and the role research plays in improving outcomes for ALK-positive cancers.
-
A Study of Gilteritinib in Adults with Advanced ALK-Positive Non-small Cell Lung Cancer (NSCLC) Sponsored by Astellas
This trial is for patients progressing on >1 prior ALK inhibitor with measurable, locally advanced or metastatic, ALK-positive non-small cell lung cancer who have experienced alectinib as their only prior ALK inhibitor regimen, or have received lorlatinib as one of their prior ALK inhibitor regimens.